18 October 2019 - Cipher Pharmaceuticals today announced it has received Health Canada approval, on 10 October 2019, for Trulance (plecanatide), a guanylate cyclase-C agonist in the form of a once-daily tablet for the treatment of adults with irritable bowel syndrome with constipation.

Consistent with its strategy to focus on partnering assets, Cipher is in the process of selecting a distribution partner for Trulance that possesses the expertise and scale to successfully bring this novel product to market.

Cipher acquired the Canadian rights to develop, market, distribute and sell Trulance from Bausch Health.

Read Cipher Pharmaceuticals press release